Physician profile
Kerry Keely
NPI 1659438380
$5,114.92
in general payments reported to CMS, 2019-2025
28 companies · $552 in 2025
The $552 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $252 · 2021: $816 · 2022: $878 · 2023: $887 · 2024: $765 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,204.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $573.92 | 2019-2025 | Hydrus Microstent, Simbrinza, Clareon |
| Sun Pharmaceutical Industries INC. | $558.21 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $512.98 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $444.26 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $415.19 | 2019-2021 | |
| Glaukos Corporation | $413.09 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Oyster Point Pharma, INC. | $398.50 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Kala Pharmaceuticals, INC. | $243.44 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $203.67 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $175.63 | 2019-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $168.85 | 2019-2023 | |
| Abbvie INC. | $131.56 | 2022-2025 | |
| Amgen INC. | $120.25 | 2024 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $113.40 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $103.21 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $77.14 | 2021-2024 | Oxervate |
| Allergan, INC. | $72.84 | 2019-2021 | |
| Astellas Pharma US INC | $65.38 | 2024 | Izervay |
| New World Medical,INC. | $61.02 | 2023 | |
| Sight Sciences, INC. | $45.64 | 2020-2023 | Tearcare System |
| Johnson & Johnson Surgical Vision, INC. | $43.02 | 2025 | Tecnis Iol |
| Shire North American Group INC | $42.46 | 2019 | |
| Mallinckrodt Enterprises LLC | $37.89 | 2019 | |
| Rxsight INC | $22.40 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Ivantis, INC | $20.70 | 2021 | |
| Rayner Intraocular Lenses Limited | $18.73 | 2022 | |
| Thea Pharma INC. | $17.83 | 2024 | Iyuzeh |
| Optos, INC. | $13.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Keely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.